Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation - Related Studies

Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation

This study is ongoing, but not recruiting participants.

Study NCT00016068. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer-Related Problem/Condition

2	Additional conditions recognized in this trial
		Cytomegalovirus Infections
		Infection

3	More general conditions related to this trial
		DNA Virus Infections
		Herpesviridae Infections
		Virus Diseases

4	Interventions listed in this trial
		ganciclovir
		valganciclovir

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antiviral Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Fred Hutchinson Cancer Research Center
		National Cancer Institute (NCI)